This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Oncology Podcasts

Prostate Cancer Podcast Series

Xofigo

The Xofigo
®▼
(radium-223 dichloride) series

Description

Xofigo, radium-223 dichloride, a treatment that has been indicated for the treatment of eligible men with metastatic castration-resistant prostate cancer (mCRPC) for over 10 years. So, what is its role in today’s clinical practice? Listen to our 20-minute podcasts below to hear from multidisciplinary experts in prostate cancer.

Access each podcast episode below as well as a short reflective learning guide developed to empower your learning. Each learning guide includes:

  • Key learning points for each podcast.
  • Reflective learning questions to best improve the learnings from each episode and to aid application of knowledge.
  • A certificate of completion.
Episode 1 – Why treat with Xofigo?

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible mCRPC patients in their clinics.

Episode 1
  • Dr.-Omi-Parikh_Intro-Page
    Dr Omi Parikh
    Consultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group.
  • Dr.-Ellie-Cradock_Intro-Page
    Ellie Cradock
    Lead Molecular Radiotherapy Manager at the University Hospitals Bristol NHS Foundation Trust.
Optimising patient identification & referral

Hear from the perspective of both a leading oncologist and nuclear medicine consultant how they optimise the treatment and referral pathway for their patients.

Episode 2
  • Dr.-Julia-Murray_Intro-Page
    Dr Julia Murray
    Consultant clinical oncologist at The Royal Marsden NHS Foundation Trust and an honorary clinical senior lecturer at The Institute of Cancer Research, London, specialising in radiotherapy and systemic therapy for prostate cancer.
  • Dr.-Amy-Eccles_Intro-Page
    Dr Amy Eccles
    Consultant Radionuclide Radiologist and Clinical Lead for Nuclear Medicine at Imperial College Healthcare NHS Trust, London.
The Practicalities of treatment

Gain valuable insights from leading healthcare professionals as they discuss what it means practically for the treating physicians, the multidisciplinary team and patients when going on treatment with radium-223 dichloride.

Episode 3
  • Dr.-Yeepei-Song_Intro-Page
    Dr Yeepei Song
    Consultant in Clinical Oncology at The Christie Hospital.
  • Dr-Maryam-Jessop_Intro
    Dr Maryam Jessop
    Chief Nuclear Medicine Technologist at Brighton and Sussex University Hospitals.

Xofigo▼ Prescribing Information

PP-XOF-GB-0461 | February 2024

    • a
      Xofigo monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for mCRPC (other than LHRH analogues), or ineligible for any available systemic mCRPC treatment